Under construction – not a live service
Sign in
Taking people in ChinaPhase 2

Combination treatment with BRII-179, BRII-835 and PEG-IFNα for chronic hepatitis B

Tests adding BRII-179 and BRII-835 to PEG-IFNα in adults with chronic hepatitis B.

Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

Key facts

Where
Beijing, Chengdu, Guangzhou, Hangzhou, Shanghai, and Shenzhen, ChinaSee the 14 sites
Phase
Phase 2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-60 with long-term hepatitis B who already take NRTI medicine and have no liver scarring.

Age
18 to 60 years
Sex
Men and women
Disease stage
Chronic HBV infection for at least 6 months, without significant liver fibrosis or cirrhosis.
Earlier treatment
Must be on NRTI therapy with HBV DNA below the lower limit of quantification for at least 6 months.
Biomarker or test result
Serum ALT and AST at or below the upper limit of normal at screening. Body mass index of at least 18 kg/m2 and at most 32 kg/m2.

Main reasons for not taking part

  • Significant liver fibrosis or cirrhosis
  • History of hepatic decompensation
  • Diagnosed or suspected liver cancer (hepatocellular carcinoma)
  • Current or past infection with HIV, HCV or HDV
  • Known history of immune function impairment

Read by machine on 9 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 60 years old?

Source: NCT06650852, who can take part

Where in China

  • Beijing, Beijing MunicipalityHospital not named in the registryTaking people
  • Beijing, Beijing MunicipalityHospital not named in the registryTaking people
  • Beijing, Beijing MunicipalityHospital not named in the registryTaking people
  • Beijing, Beijing MunicipalityHospital not named in the registryTaking people
  • Beijing, Beijing MunicipalityHospital not named in the registryTaking people
  • Chengdu, SichuanHospital not named in the registryTaking people
  • Chengdu, SichuanHospital not named in the registryTaking people
  • Chengdu, SichuanHospital not named in the registryTaking people
  • Guangzhou, GuangdongHospital not named in the registryTaking people
  • Guangzhou, GuangdongHospital not named in the registryTaking people
  • Hangzhou, ZhejiangHospital not named in the registryTaking people
  • Shanghai, Shanghai MunicipalityHospital not named in the registryTaking people
  • Shanghai, Shanghai MunicipalityHospital not named in the registryTaking people
  • Shenzhen, GuangdongHospital not named in the registryTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Brii Biosciences Limited
Trial code
NCT06650852
Record updated
22 October 2026
Original description
This Phase 2, randomized, double-blind study will evaluate the clinical efficacy and safety of the combination therapy of BRII-179, BRII-835, plus PEG-IFNα compared to PEG-IFNα in adult participants with chronic HBV infection without cirrhosis receiving neucloes(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.Read full original descriptionShow less

A Phase 2 Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and Pegylated Interferon Alpha (PEG-IFNα) in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

This Phase 2, randomized, double-blind study will evaluate the clinical efficacy and safety of the combination therapy of BRII-179, BRII-835, plus PEG-IFNα compared to PEG-IFNα in adult participants with chronic HBV infection without cirrhosis receiving neucloes(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.

Inclusion: Male or female aged 18-60 years; Body mass index ≥ 18 kg/m2 and ≤ 32 kg/m2; Chronic HBV infection for ≥ 6 months; On NRTI therapy with HBV DNA < LLOQ for ≥ 6 months; Serum ALT and AST ≤ ULN at screening visit.

Exclusion: Any clinically significant chronic medical conditions other than chronic HBV infection that makes the participant unsuitable for participation in the study; History of clinically significant chronic liver disease from any cause other than chronic HBV infection; History of hepatic decompensation; Current or past history of infection with HIV, HCV or HDV; Known history of immunological function impairment; History of intolerance to intramuscular or subcutaneous injection; Any laboratory test abnormality that may contradict treatment with PEG-IFNα; Significant liver fibrosis or cirrhosis; Diagnosed or suspected hepatocellular carcinoma.

ClinicalTrials.gov NCT06650852